This article is a correction to:
Second malignant neoplasms within 5 years from first primary diagnosis in pediatric oncology patients in Canada: a population-based retrospective cohort study
Christina Ricci1†
Divya Subburaj2†Kate Lim3*†Neetu Shukla1Jaskiran Kaur4Lin Xie1Meghan Laverty1Dianne Zakaria1Jason Pole5,6Marie-Claude Pelland-Marcotte7,8Randy Barber9Sara J. Israels10Thai-Hoa Tran11,12Sapna Oberoi10,13Samuele Renzi14,15Tamara MacDonald16,17Lillian Sung14,18Ketan Kulkarni2*- 1Lifespan Chronic Disease and Conditions Division, Public Health Agency of Canada, Ottawa, ON, Canada
- 2Department of Pediatrics, Division of Hematology-Oncology, Izzak Walton Killam (IWK) Health Centre, Halifax, NS, Canada
- 3Faculty of Medicine, Dalhousie University, Halifax, NS, Canada
- 4Surveillance Systems and Data Management Division, Public Health Agency of Canada, Ottawa, ON, Canada
- 5Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
- 6Centre for Health Sciences Research, University of Queensland, Brisbane, QLD, Australia
- 7Division of Pediatric Hematology-Oncology, CHU de Québec-Centre Mère-Enfant Soleil, Quebec City, QC, Canada
- 8Research Centre of the CHU de Québec, Axe Reproduction, Santé de la Mère et de l’Enfant, Quebec City, QC, Canada
- 9C17 Research Network, C17 Council, Edmonton, AB, Canada
- 10Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, MB, Canada
- 11Department of Pediatrics, Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montréal, QC, Canada
- 12Immune Diseases and Cancers Axis, CHU Sainte-Justine Research Center, Montréal, QC, Canada
- 13Department of Pediatric Hematology-Oncology, CancerCare Manitoba, Winnipeg, MB, Canada
- 14Division of Hematology Oncology, The Hospital for Sick Children, Toronto, ON, Canada
- 15Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy
- 16Department of Pharmacy, Izzak Walton Killam (IWK) Health, Halifax, NS, Canada
- 17Faculty of Health Professions, Dalhousie University, Halifax, NS, Canada
- 18Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada
By Ricci C, Subburaj D, Lim K, Shukla N, Kaur J, Xie L, Laverty M, Zakaria D, Pole J, Pelland-Marcotte M-C, Barber R, Israels SJ, Tran T-H, Oberoi S, Renzi S, MacDonald T, Sung L and Kulkarni K (2024). Front. Oncol. 14:1376652. doi: 10.3389/fonc.2024.1376652
In the published article, there was an error in the legend for Figure 5 to 7 as published. Currently it stated “This hazard ratio has been suppressed because less than 5 patients have the characteristic.” The corrected legend appears below.
“ƚ indicates this hazard ratio has been suppressed because less than 5 patients have the characteristic.”
Figure 5
Figure 5 Forest plot depicting the variables and adjusted hazard ratio for SMN. ƚ indicates this hazard ratio has been suppressed because less than 5 patients have the characteristic.
Figure 6
Figure 6 Forest plot depicting the variables and adjusted hazard ratio for SMN developed within 0-2 years. ƚ indicates this hazard ratio has been suppressed because less than 5 patients have the characteristic.
Figure 7
Figure 7 Forest plot depicting the variables and adjusted hazard ratio for SMN developed within 2-5 years. ƚ indicates this hazard ratio has been suppressed because less than 5 patients have the characteristic.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: oncology, pediatrics, risk factors, early second malignant neoplasm (early SMN), Canada, surveillance
Citation: Ricci C, Subburaj D, Lim K, Shukla N, Kaur J, Xie L, Laverty M, Zakaria D, Pole J, Pelland-Marcotte M-C, Barber R, Israels SJ, Tran T-H, Oberoi S, Renzi S, MacDonald T, Sung L and Kulkarni K (2024) Corrigendum: Second malignant neoplasms within 5 years from first primary diagnosis in pediatric oncology patients in Canada: a population-based retrospective cohort study. Front. Oncol. 14:1418512. doi: 10.3389/fonc.2024.1418512
Received: 16 April 2024; Accepted: 22 April 2024;
Published: 10 May 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Ricci, Subburaj, Lim, Shukla, Kaur, Xie, Laverty, Zakaria, Pole, Pelland-Marcotte, Barber, Israels, Tran, Oberoi, Renzi, MacDonald, Sung and Kulkarni. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kate Lim, kate.lim@dal.ca; Ketan Kulkarni, Ketan.Kulkarni@iwk.nshealth.ca
†These authors share first authorship